Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later

H Briem, A Safary

Rannsóknarafurð: Framlag til fræðitímaritsGreinritrýni

Útdráttur

An inactivated vaccine against hepatitis A was administered as a single 1,440 enzyme-linked immunosorbent assay (ELISA) units dose at month 0 with a booster at month 6 to 200 subjects divided into two age groups: group 1, 20-39 years (n = 134) and group II, 40-62 years (n = 66). At day 15, the seropositivity rates were 90% and 77% in groups I and II, respectively. At month 1 the seropositivity rate was 97% in both groups. At month 6 the seropositivity rates were 94% and 88% in groups I and II, respectively. One month after the booster, at month 7, 100% in both groups had become seropositive. The vaccine was well tolerated and did not cause any severe reactions. The results indicate that a single high vaccine dose offers protection against hepatitis A virus (HAV) for at least 6 months in the majority of cases where rapid vaccination is required even in travellers of older age. A booster dose will ensure long-term protection.
Upprunalegt tungumálEnska
FræðitímaritJournal of Medical Virology
DOI
ÚtgáfustaðaÚtgefið - des. 1994

Önnur efnisorð

  • Adult
  • Age Factors
  • Consumer Product Safety
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Hepatitis A
  • Hepatitis A Antibodies
  • Hepatitis A Vaccines
  • Hepatitis A Virus, Human
  • Hepatitis Antibodies
  • Humans
  • Male
  • Middle Aged
  • Vaccination
  • Vaccines, Inactivated
  • Viral Hepatitis Vaccines

Fingerprint

Sökktu þér í rannsóknarefni „Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later“. Saman myndar þetta einstakt fingrafar.

Vitna í þetta